Abraxis BioScience Acquires From the Buck Institute Exclusive Worldwide Intellectual Property Rights for Technologies Designed to Discover New Drug Candidates

Abraxis BioScience, Inc., an integrated, global biopharmaceutical company, announced an agreement with the Buck Institute for Age Research that provides Abraxis with the exclusive worldwide intellectual property rights for technologies designed to generate novel therapeutics and identify new drug discovery targets.
Abraxis